In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a team from the Faculty of Medicine at Hebrew University. Dr. Raphael Benhamou and M.Sc. student Liann Kassabri have developed innovative druglike molecules capable of degrading HuR, a key RNA-binding protein that stabilizes oncogenes and fuels cancer progression.